These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29436729)

  • 1. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
    Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P; Bonanni A; Ghiggeri GM
    BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
    Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
    Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.
    Colucci M; Carsetti R; Serafinelli J; Rocca S; Massella L; Gargiulo A; Lo Russo A; Capponi C; Cotugno N; Porzio O; Onetti Muda A; Palma P; Emma F; Vivarelli M
    Front Immunol; 2019; 10():1653. PubMed ID: 31379849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
    Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
    Fribourg M; Cioni M; Ghiggeri G; Cantarelli C; Leventhal JS; Budge K; Bin S; Riella LV; Colucci M; Vivarelli M; Angeletti A; Perin L; Cravedi P
    Front Immunol; 2021; 12():726428. PubMed ID: 34621271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
    Basu B; Mahapatra TK; Mondal N
    Pediatrics; 2015 Jul; 136(1):e132-9. PubMed ID: 26101364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
    Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
    Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?
    Subun C; Suwannahitatorn P; Webb H; Tullus K
    Arch Dis Child; 2021 Jul; 106(8):815-818. PubMed ID: 33177054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.
    Miyabe Y; Takei T; Iwabuchi Y; Moriyama T; Nitta K
    Clin Exp Nephrol; 2016 Feb; 20(1):103-10. PubMed ID: 26138356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
    Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
    BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome.
    Kamei K; Ogura M; Sato M; Ito S; Ishikura K
    Pediatr Nephrol; 2018 Jun; 33(6):1013-1018. PubMed ID: 29426974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
    Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.
    Bertrand Q; Mignot S; Kwon T; Couderc A; Maisin A; Cambier A; Baudouin V; Peyneau M; Deschênes G; Hogan J; Dossier C
    Pediatr Nephrol; 2022 Feb; 37(2):357-365. PubMed ID: 34132894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
    Basu B; Angeletti A; Islam B; Ghiggeri GM
    Front Immunol; 2022; 13():805697. PubMed ID: 35222385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome.
    Colucci M; Angeletti A; Zotta F; Carsetti R; Lugani F; Ravà L; Ravani P; Emma F; Ghiggeri GM; Vivarelli M
    Kidney Int; 2023 Sep; 104(3):577-586. PubMed ID: 37385541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.